Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Estimated conditional OS shows upfront TKI benefit in mRCC

Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Key clinical point: Conditional overall survival estimates may help clinicians adjust surveillance planning in patients with mRCC.

Major finding: At all survival times after the start of TKI therapy, conditional overall survival gradually increased when compared with baseline survival estimates.

Study details: Retrospective review of records on 1,131 patients with mRCC.

Disclosures: The study was supported by a National Research Foundation of Korea research grant funded by the Ministry of Science and Information and Communications Technology and by a Korea Health Technology R&D Project grant through the Korea Health Industry Development Institute funded by the Ministry of Health and Welfare in South Korea. No conflicts of interest were reported.

Read the article.

Citation:

Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030